Medical oncologist Dr Philipp Ivanyi joined us at ESMO 2023 to share his thoughts on the latest precision oncology data to emerge from the congress and the possible impact on clinical practice. 

Clinical Takeaways

Cancer of unknown primary

  • CUPISCO: In patients with newly diagnosed, unfavourable, non-squamous CUP that responded to induction CTX, CGP with MGT improved PFS, thereby supporting a precision oncology approach in these patients
  • CUP-ONE: CTID molecular-expression classifier demonstrated similar performance overall to specialist C-IHC
  • Fudan CUP-001: Site-specific treatment guided by the approved 90-gene expression assay resulted in more therapy options, and significantly improved PFS with favourable OS vs empirical chemotherapy in patients with de novo CUP

Diagnostic

  • ARCAGEN: Molecular profiling of rare cancers identified many targetable alterations, and should be more routinely performed

Treatment

  • DESTINY-PanTumor01 (DPT-01): In heavily pretreated patients with limited treatment options, T-DXd demonstrated encouraging anticancer activity and long DoR across multiple tumour types with HER2m and a range of HER2 expression levels
  • LIBRETTO-531: First-line selpercatinib prolonged PFS, improved ORR, and achieved a better OS vs MKIs, and should now be considered the preferred first-line standard of care for patients with advanced RET-mutant MTC

 

  • Help physicians translate the latest Precision Oncology data from ESMO 2023 into clinical practice.

Dr Ivanyi is the Assistant Medical Director Hematology, Oncology, Hemostasis, Stem Cell Transplantation (Palliative Care) at the Hanover Medical School. He is also Head of the Clinical Trial Unit for Medical Oncology

Dr Ivanyi also serves as:

  • Steering Committee and Spokesman, Immune Cooperative Oncology Group, Comporehensive Cancer Center, Claudia von Schelling Center (CCC-H)
  • Board Member, Clinical Trial Steering Committee, CCC-H
  • Spokesman Interdisciplinary Working Group Kidney Cancer, Germany Cancer Society (IAGN-DKG)

His research interests include clinical and experimental Research in Urogenital Cancer, Head and Neck Cancer, Sarcoma, Rare Cancers, Targeted Therapies. He has >80 SCI Publication and has a depth of experience in >50 Clinical Trials Phase I – IV (PI and Country Lead).

Dr Philipp Ivanyi has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AIM, AIO, Apogepha, Astella, Astra Zeneca, Bayer, BMS, ClinSol, Deciphera, Deutsche Gesellschaft für Thoraxchirurgie, DKG-Onkoweb, EISAI, EMD-Serono, EUSA, FoFM, GSK, Id-Institut, Ipsen (Europe), Lilly, MedKom, Metaplan, MedWiss, Merck Serono (Global), MSD, MTE-Academy, New Concept Oncology, Niedersächsische Krebsgesellschaft, Novartis, Onkowissen-tv.de, Pharma Mare, Pfizer, Roche, Schmitz-Communikation, Solution Academy,Stiftung Immunonkologie, StreamedUP!, ThinkWired!, Vivantis and Wilhelm Sander Stiftung.

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
PRECISION ONCOLOGY CONNECT

PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Amoy Diagnostics, Bayer, Pierre Fabre Laboratories and Thermo Fisher Scientific.

Meet the experts Independent IME approved

Other programmes of interest

podcast Video podcast
Oncology Endocrinology Rare diseases 
Exploring the role of targeted radiopharmaceutical treatment in NETs

PRRT and emerging strategies in neuroendocrine tumours

Experts
Prof. Ken Herrmann, Dr Heloisa Soares, Oncology Brothers (Moderators)
Endorsed by
NANETS
CommNETs Neuroendocrine Cancer UK
  • download Downloadable
    Resources
  • clock 21 MIN
  • calendar Oct 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from ITM.
ipcv Interactive Patient Case Video (IPCV)
Oncology 
Shared decision-making for prostate cancer patients

Early treatment intensification with a PARPi plus ARPI combination

Experts
Prof. Gunhild von Amsberg
Endorsed by
ZERO Urobel VZW | ASBL
EAUN
  • clock 25 MIN
  • calendar Sep 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from AstraZeneca 
conference-update Conference update
Oncology 
Oncogene-addicted NSCLC highlights from WCLC 2025

Expert insights on the latest data in oncogene-addicted non-small cell lung cancer 

Experts
Dr Devika Das
Endorsed by
Exon20group Biomarker Collaborative ICAN international cancer advocacy network
Lung Cancer Europe
Lung Cancer Research Foundation
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Sep 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Bayer.
podcast Video podcast
Oncology 
Understanding the BRAFV600E testing and treatment landscapes in NSCLC

Two perspectives, one aim: A pathologist and a medical oncologist in discussion

Experts
Assoc. Prof. Umberto Malapelle, Prof. Nicolas Girard
Endorsed by
ISLB
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Sep 2025
  • Non-accredited Independent Medical Education

This content is intended for HCPs outside the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts.